文献速递甲状腺疾病

丹麦PRETHYR多中心研究:妊娠期抗甲状腺药物治疗首报

Antithyroid drug treatment in pregnancy: a first report from the Danish PRETHYR multicenter study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

丹麦PRETHYR多中心研究纳入121名妊娠期女性,其中97.5%为Graves病,旨在调查妊娠期甲状腺功能亢进的治疗实践及接受抗甲状腺药物(ATD)治疗者的特征。在102名孕前已知甲状腺疾病且未接受根治治疗的女性中,58.8%在妊娠期接受ATD治疗,这些患者更多由内分泌科医生在受孕时管理,且孕前TSH更低、总T3和TSH受体抗体更高。治疗主要限于孕早期前半段,通常在孕中或孕晚期停药。

要点

  • 孕前已知甲状腺疾病且未根治者中,58.8%妊娠期接受ATD治疗。
  • 接受ATD者更多由内分泌科医生管理,孕前TSH更低、总T3和TRAb更高。
  • ATD治疗多限于孕早期前半段,孕中或孕晚期 generally 停药。

核心结论

  • 该研究首次报告丹麦多中心妊娠期Graves病及ATD治疗女性的临床管理实践。

研究设计与样本

  • 丹麦多中心研究PRETHYR纳入121名妊娠期女性,其中97.5%患Graves病,通过问卷和病历回顾收集资料。

主要发现

  • 102名孕前已知甲状腺疾病且未根治的女性中,58.8%(n=60)妊娠期接受ATD治疗。
  • 接受ATD者更多由内分泌科医生在受孕时管理,且孕前TSH更低、总T3和TSH受体抗体更高。
  • 治疗主要限于孕早期前半段,通常在孕中或孕晚期停药。
  • 孕前使用甲巯咪唑者中59.1%转换为丙硫氧嘧啶,10.7%从丙硫氧嘧啶转换为甲巯咪唑。

临床怎么用

  • 妊娠期Graves病甲亢应接受治疗以预防母胎并发症,ATD选择与转换需权衡副作用。
  • 孕前已知甲状腺疾病且未根治者,妊娠期是否启用ATD需结合TSH、总T3和TRAb水平及专科管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hyperthyroidism caused by Graves' disease (GD) should be treated in pregnancy to prevent maternal and fetal complications; however, side effects observed with antithyroid drugs (ATDs) may complicate current clinical management. OBJECTIVE: To investigate current treatment practices for hyperthyroidism during pregnancy in Denmark and the characteristics of women receiving ATDs. METHODS: The Danish multicenter study PRETHYR (Pregnancy Investigations on Thyroid Disease) included women with GD and women treated with ATDs in pregnancy. Maternal characteristics, preconception measurements of TSH, total T3, and TSH-receptor antibodies, and information on the clinical management and treatment before and during pregnancy, were obtained through patient questionnaires and review of the medical record. RESULTS: Of the 121 women included, 97.5% had GD. Among the 102 women with known thyroid disease preconceptionally and no prior definitive treatment, 58.8% (n = 60) received ATDs in pregnancy. These women were more often managed by endocrinologist at conception, had lower preconception TSH, and higher total T3 and TSH-receptor antibodies compared to women not treated with ATDs. Treatment was predominantly confined to the first half of the first trimester and generally discontinued by the second or third trimester. Before conception, 59.1% of women treated with methimazole were switched to propylthiouracil, and 10.7% were switched from propylthiouracil to methimazole. CONCLUSION: This is the first report from a multicenter study on pregnant women with GD and women treated with ATDs during pregnancy. The results provide insight into the current clinical treatment practices of hyperthyroidism in Denmark.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Uldall-Torp NM, Pedersen IB, Carlé A, et al. Antithyroid drug treatment in pregnancy: a first report from the Danish PRETHYR multicenter study. J Clin Endocrinol Metab. 2026. PMID: 41790746. doi:10.1210/clinem/dgag099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。